Download PDF
Pharmacopsychiatry 2024; 57(03): 101-103
DOI: 10.1055/a-2290-6470
Editorial

Medical Cannabis in Psychiatry

Kirsten R. Müller-Vahl
1   Clinic for Psychiatry, social psychiatry and psychotherapy, Hannover Medical School, Hannover, Germany
,
Georg Juckel
2   Department of Psychiatry Psychotherapy and Preventive Medicine, LWL University Hospital of the Ruhr University Bochum, Bochum, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Keywords

cannabis - tourette-s disorder - depression


Publication History

Received: 23 February 2024
Received: 06 March 2024

Accepted: 07 March 2024

Article published online:
07 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Behr HG. Von Hanf ist die Rede, Kultur und Politik einer Droge. Sphinx Verlag Basel. 1982
    PubMedGoogle Scholar
  • 2 Fankhauser M. Rückblick. Cannabis in medicine - a medical-historical review. MMW Fortschr Med 2022; 164: 24-25 German DOI: 10.1007/s15006-022-1855-2.. PMID: 36195789
    CrossrefPubMedGoogle Scholar
  • 3 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use: A systematic review and Meta-analysis. JAMA 2015; 313: 2456-2473 DOI: 10.1001/jama.2015.6358.
    CrossrefPubMedGoogle Scholar
  • 4 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2015; 314: 520 DOI: 10.1001/jama.2015.8253.
    CrossrefPubMedGoogle Scholar
  • 5 Krumholz HM, Nuti SV, Downing NS. et al. Mortality, hospitalizations, and expenditures for the medicare population. JAMA 2015; 314: 837 DOI: 10.1001/jama.2015.10005.
    CrossrefPubMedGoogle Scholar
  • 6 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2015; 314: 2308
    CrossrefPubMedGoogle Scholar
  • 7 Whiting PF, Wolff RF, Deshpande S. et al. Cannabinoids for medical use. JAMA 2016; 315: 1522
    PubMedGoogle Scholar
  • 8 Abrams DI. The therapeutic effects of cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med 2018; 49: 7-11 DOI: 10.1016/j.ejim.2018.01.003.
    CrossrefPubMedGoogle Scholar
  • 9 Müller-Vahl KR. Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmcopsychiatry 2024; 57: 104-114
    PubMedGoogle Scholar
  • 10 Dammann I, Rohleder C, Leweke FM. Cannabidiol and its potential evidence-based psychiatric benefits – a critical review. Pharmacopsychiatry 2024; 57: 115-132
    PubMedGoogle Scholar
  • 11 Szejko N, Becher E, Heimann F. et al. Medical use of different cannabis strains: Results from a large prospective survey in Germany. Pharmcopsychiatry 2024; 57: 133-140
    PubMedGoogle Scholar
  • 12 Das A, Hendershot C, Husain M. et al. Perceptions, experiences, and patterns of cannabis use in individuals with mood and anxiety disorders in the context of cannabis legalisation and medical cannabis program in Canada - a qualitative study. Pharmcopsychiatry 2024; 57: 141-151
    PubMedGoogle Scholar
  • 13 Karst M. Overview: Chronic pain and cannabis-based medicines. Pharmcopsychiatry 2024; 57: 152-159
    PubMedGoogle Scholar
  • 14 Broers B, Bianchi F. Cannabinoids for behavioral symptoms in dementia: An overview. Pharmcopsychiatry 2024; 57: 160-168
    PubMedGoogle Scholar